Advanced searches left 3/3

Metastatic Non-Small Cell Lung Cancer - Europe PMC

Summarized by Plex Scholar
Last Updated: 27 April 2022

* If you want to update the article please login/register

Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non-small-cell lung cancer.

Treatment is a challenge for patients with distant metastasis heterogeneity in tumors of NSCLC patients. We arranged the primary tumors and metastatic tissues of 48 NSCLC patients through 363 tumor-related gene panels to look at gene mutations in primary tumors and metastatic tissues of primary tumors and metastatic tissues, as well as screen candidate carcinogenic and metastatic mutations. EGFR amplification was more prevalent in the metastatic group than in the non-metastatic group, according to the copy number variation mutation spectrum results. The number of subcutaneous mutations in the primary and metastatic lesions in the metastasis group was significantly different, compared to those in primary lesions; the number of subclonal lesions was greater than that in primary lesions. The initial and metastatic lesions' gene mutations of NSCLC were discovered by our researchers, who discovered particular mutations related to metastasis of NSCLC.

Source link: https://europepmc.org/article/MED/35466584


Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups.

Thus, we wanted to determine the prevalence and clinical relevance of BRAF mutations in a real-life population of advanced-NSCLC cells, as well as the potential prognostic value of specific genetic variations. Conclusions A total of 44 BRAF mut NSCLC patients were included in the study. According to V600E vs. non-V600E mutations, no significant differences in survival outcomes and treatment response were reported, although a trend toward prolonged PFS was observed in the V600E subgroup. Overall, ECOG PS and age had a major effect on OS, however bone lesions were associated with shorter PFS.

Source link: https://europepmc.org/article/MED/35454926


Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice.

To dissect PD-1 blockade efficacy in non-small cell lung cancer, we want to delineate and then incorporate both the predictive and prognostic effects of the metastatic-organ landscape. Methods Anonyms: A total of 2062 NSCLC patients from a double-arm controlled trial, two immunotherapy trials, and a real-world cohort were included. Patients with various organ-specific metastases differed in response to immunotherapy, and those with brain and adrenal gland metastases lived longer than others [overall survival, 0. 0106; progression-free survival, 0. 0167]. In the OAK training cohort, the METscore was capable of integrating both predictive and prognostic results of the entire landscape and dissected OS results of NSCLC patients, as well as some cancerous ones. METscore was also useful to patients receiving PD-1 blockade as first-line therapy both in the clinical trials and in the real-life scenario.

Source link: https://europepmc.org/article/MED/35410334


Effect of acute aerobic exercise before immunotherapy and chemotherapy infusion in patients with metastatic non-small-cell lung cancer: protocol for the ERICA feasibility trial.

Patients with metastatic non-small cell lung cancer suffer from numerous signs related to disease and therapy, which may also affect the patient's overall wellbeing. Physical activity can also raise treatment response, particularly because of its reported effects on the immune system. In addition to its benefits on quality of life and exhaustion, physical fitness can also improve treatment outcomes, particularly due to its documented effects on the immune system. The ERICA research is designed to determine the success of a closely monitored acute physical fitness program that was initiated immediately prior to immune-chemotherapy infusion in patients with mNSCLC. Patients newly diagnosed with mNSCLC will be randomly assigned to the 'exercise' or the 'control' group. Participants in both groups will receive Physical Activity reports and two nutritional assessments at baseline and during the last medical cycle. Participants in the exercise group will be treated to a three-month course including a guided acute physical exercise session prior to immune-chemotherapy infusion, as well as unsupervised home-based walking program with an activity tracker.

Source link: https://europepmc.org/article/MED/35393316


Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060).

Lung cancer is one of the most common causes of brain tumors and is always associated with poor prognosis. Our results showed that matched brain metastases compared to primary lung tumors showed reduced tumor infiltrating lymphocytes, a larger number of neutrophils infiltrating lymphocytes, decreased scores of immune-related signatures, and a smaller percentage of tumor microenvironment immune type I tumors in comparison to primary lung tumors compared to primary lung tumors. In addition, gene set enrichment testing revealed that some gene sets associated with the immune response were enriched in the metachronous group, while other gene sets associated with differentiation and metastasis were enriched in the synchronous group of primary lung tumors, according to the synchronous group. In addition, the tumor immune microenvironment between paired brain metastases and primary lung tumors in the metachronous group was higher in the metachronous group than in the synchronous group. Brain metastatic tumors are more immunosuppressed than primary lung tumors, according to our findings, which may help guide immunotherapeutic strategies for NSCLC brain metastases.

Source link: https://europepmc.org/article/MED/35402080


The efficacy and safety of immunotherapy and palliative radiotherapy in metastatic non-small cell lung cancer patients: a systematic review and meta-analysis

Primary aim: Palliative radiotherapy is commonly used in the treatment of metastatic non-small cell lung cancer. However, it is also unknown if pRT could have influenced the outcomes of mNSCLC patients who used immune checkpoint inhibitors as maintenance therapy. Improved DCR, OS, and PFS were notably associated with increased DCR, OS, and PFS. ICIs were also attributed to improved DCR, OS, and PFS. Patients receiving ICIs plus pRT showed no statistically significant difference in comparison to those in the control group in safety studies of III-IV grade adverse events. Patients with mNSCLC's mNSCLC may benefit from ICI and pRT combination therapy with acceptable incidences of grade III-IV AEs in patients.

Source link: https://europepmc.org/article/PPR/PPR474561

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions